Malin Corporation PLC
ISEQ:MLC
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4.34
6.45
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Malin Corporation PLC
Cash from Financing Activities
Malin Corporation PLC
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Malin Corporation PLC
ISEQ:MLC
|
Cash from Financing Activities
-€800k
|
CAGR 3-Years
77%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ICON PLC
NASDAQ:ICLR
|
Cash from Financing Activities
-$688.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-60%
|
|
Malin Corporation PLC
Glance View
Malin Corp. Plc.invests and supports innovative life sciences companies, which develops exceptional science and technology to deliver transformative outcomes for patients. The company is headquartered in Dublin, Dublin and currently employs 5 full-time employees. The company went IPO on 2015-03-25. The Company’s assets give investors access to life sciences businesses with exposure across diverse modalities, therapeutic areas and geographies. Its business includes Poseida, Viamet, Xenex, CG Oncology, Wren, KNOW Bio and Artizan. Poseida is a clinical-stage biopharmaceutical company building a pipeline of Chimeric antigen receptor T cell (CAR-T) product candidates, initially focused on the treatment of hematological malignancies, including multiple myeloma, and solid tumours, like prostate cancer. The company is also developing two CAR-T therapies: autologous and allogeneic. Xenex is a commercial-stage medical device company focused on reducing healthcare-associated infections with its non-mercury, full-spectrum disinfection LightStrike Germ-Zapping robots. CG Oncology is an oncolytic immunotherapy company that is intensely focused on developing bladder-saving therapeutics for patients with bladder cancer.
See Also
What is Malin Corporation PLC's Cash from Financing Activities?
Cash from Financing Activities
-800k
EUR
Based on the financial report for Jun 30, 2024, Malin Corporation PLC's Cash from Financing Activities amounts to -800k EUR.
What is Malin Corporation PLC's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
77%
Over the last year, the Cash from Financing Activities growth was 99%. The average annual Cash from Financing Activities growth rates for Malin Corporation PLC have been 77% over the past three years .
You don't have any saved screeners yet
